Abstract
The human leukocyte antigen (HLA) system is a highly polymorphic family of genes involved in immunity and responsible for identifying self versus non-self. HLA typing is essential for solid organ and bone marrow transplantation as well as in non-transplant settings such as disease association and pharmacogenomics. Typing of HLA genes differs from most molecular testing as, rather than evaluating differences from an accepted “wild-type” gene, it must distinguish between thousands of similar, but distinct alleles. This article will describe the HLA system and nomenclature. We will then discuss clinical uses of HLA typing including solid organ transplantation, hematopoietic stem cell transplantation, evaluation of platelet refractory patients, disease association, and pharmacogenetics. Finally, we describe common molecular methods of HLA typing.
Similar content being viewed by others
References
Klein J, Sato A (2000) The HLA system. First of two parts. N Engl J Med 343(10):702–709 Review.2
Mosaad YM (2015) Clinical role of human leukocyte antigen in health and disease. Scand J Immunol 82(4):283–306. https://doi.org/10.1111/sji.12329 Review.3
Gragert L, Madbouly A, Freeman J, Maiers M (2013) Six-locus high resolution HLA haplotype frequencies derived from mixed-resolution DNA typing for the entire US donor registry. Hum Immunol 74(10):1313–1320
Kamoun M, Hollenbach JA, Mack SJ et al (2016) Molecular HLA typing. In: Leonard D (ed) Molecular pathology in clinical practice, 2nd edn. Springer International Publishing, Springer Science+Business Media, Switzerland, pp 867–885
Marsh SG, Albert ED, Bodmer WF et al (2010) Nomenclature for factors of the HLA system, 2010. Tissue Antigens 75(4):291–455
Fung MK, Benson K (2015) Using HLA typing to support patients with cancer. Cancer Control 22(1):79–86 Review
Nunes E, Heslop H, Fernandez-Vina M, Taves C, Wagenknecht DR, Eisenbrey AB, Fischer G, Poulton K, Wacker K, Hurley CK, Noreen H, Sacchi N (2011) Definitions of histocompatibility typing terms: Harmonization of Histocompatibility Typing Terms Working Group. Hum Immunol 72(12):1214–1216
Sanchez-Mazas A, Vidan-Jeras B, Nunes JM, Fischer G, Little A-M, Bekmane U, Buhler S, Buus S, Claas F, Dormoy A, Dubois V, Eglite E, Eliaou J-F, Gonzalez-Galarza F, Grubic Z, Ivanova M, Lie B, Ligeiro D, Lokki ML, Martins da Silva B, Martorell J, Mendonça D, Middleton D, Papaioannous Voniatis D, Papasteriades C, Poli F, Riccio ME, Spyropoulou Vlachou M, Sulcebe G, Tonks S, Toungouz Nevessignsky M, Vangenot C, van Walraven A-M, Tiercy J-M (2012) Strategies to work with HLA data in human populations for histocompatibility, clinical transplantation, epidemiology and population genetics: HLA-NET methodological recommendations. Int J Immunogenet 39(6):459–476
Organ Procurement and Transplantation Network Policies. Health resources and services administration. Effective 6/13/2018. https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf. Accessed 7/8/2018
Garces JC, Giusti S, Staffeld-Coit C, Bohorquez H, Cohen AJ, Loss GE (2017) Antibody-mediated rejection: a review. Ochsner J 17(1):46–55
Zachary AA, Leffell MS (2016) HLA mismatching strategies for solid organ transplantation—a balancing act. Front Immunol 7:575. https://doi.org/10.3389/fimmu.2016.00575 eCollection 2016. Review
Paramesh AS, Zhang R, Baber J, Yau CL, Slakey DP, Killackey MT, Ren Q, Sullivan K, Heneghan J, Florman SS (2010) The effect of HLA mismatch on highly sensitized renal allograft recipients. Clin Transpl 24(6):E247–E252. https://doi.org/10.1111/j.1399-0012.2010.01306.x
Heidt S, Haasnoot GW, van Rood JJ, Witvliet MD, Claas FHJ (2018) Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients. Kidney Int 93(2):491–500. https://doi.org/10.1016/j.kint.2017.07.018
Transplant Referral Timing Guidelines. National Marrow Donor Program. Effective 10/2017. https://bethematchclinical.org/transplant-indications-and-outcomes/referral-timing-guidelines. Accessed 7/12/18
Fleischhauer K, Shaw BE, Gooley T et al (2012) International Histocompatibility Working Group in Hematopoietic Cell Transplantation. Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study. Lancet Oncol 13(4):366–374
Petersdorf EW (2007) Risk assessment in haematopoietic stem cell transplantation: histocompatibility. Best Pract Res Clin Haematol 20(2):155–170
Crocchiolo R, Ciceri F, Fleischhauer K, Oneto R, Bruno B, Pollichieni S, Sacchi N, Sormani MP, Fanin R, Bandini G, Bonifazi F, Bosi A, Rambaldi A, Alessandrino PE, Falda M, Bacigalupo A (2009) HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. Bone Marrow Transplant 44(9):571–577
Gragert L, Eapen M, Williams E, Freeman J, Spellman S, Baitty R, Hartzman R, Rizzo JD, Horowitz M, Confer D, Maiers M (2014) HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry. N Engl J Med 371(4):339–348
Kekre N, Antin JH (2014) Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. Blood 124(3):334–343
Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, Bolaños-Meade J, Fuchs EJ, Wagner-Johnston N, Swinnen LJ, Huff CA, Matsui WH, Gladstone DE, McCurdy SR, Borrello I, Gocke CB, Shanbhag S, Cooke KR, Ali SA, Brodsky RA, DeZern AE, Luznik L, Jones RJ, Ambinder RF (2018) Haploidentical bone marrow transplantation with post-transplant cyclophosphamide using non–first-degree related donors. Biol Blood Marrow Transplant 24(5):1099–1102
Fletcher CH, DomBourian MG, Millward PA (2015) Platelet Transfusion for Patients with Cancer. Cancer Control 22(1):47–51. Review
Díaz-Peña R, López-Vázquez A, López-Larrea C (2012) Old and new HLA associations with ankylosing spondylitis. Tissue Antigens 80(3):205–213
Reveille JD (2014) An update on the contribution of the MHC to as susceptibility. Clin Rheumatol 33(6):749–757
Holoshitz J (2013) The quest for better understanding of HLA-disease association: scenes from a road less travelled by. Discov Med 16(87):93–101
Cardoso CS, Alves H, Mascarenhas M, Gonçalves R, Oliveira P, Rodrigues P, Cruz E, de Sousa M, Porto G (2002) Co-selection of the H63D mutation and the HLA-A29 allele: a new paradigm of linkage disequilibrium? Immunogenetics 53(12):1002–1008
Shear NH, Milpied B, Bruynzeel DP, Phillips EJ (2008) A review of drug patch testing and implications for HIV clinicians. AIDS 22(9):999–1007
Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CSJ, Wu JY, Chen YT (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc 86 Cancer Control January 2015, Vol. 22, No. 1. Natl Acad Sci U S A 102(11):4134–4139
Chung WH, Hung SI, Hong HS, Hsih MS, Yang LC, Ho HC, Wu JY, Chen YT (2004) Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428(6982):486
Daly AK, Donaldson PT, Bhatnagar P et al (2009) DILIGEN Study; International SAE consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 41(7):816–819
Testi M, Andreani M (2015) Luminex-based methods in high-resolution HLA typing. In: Bugert P (eds) Molecular typing of blood cell antigens. Methods Mol Biol 1310:231–245
Heinemann FM (2009) HLA genotyping and antibody characterization using the LuminexTM multiplex technology. Transfus Med Hemother 36(4):273–278
Dunckley H (2012) HLA typing by SSO and SSP methods. In: Christiansen FT, Tait Brian D (eds) Immunogenetics: methods and applications in clinical practice. Springer Science + Business Media, New York
Bunce M, O'Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ, Welsh KI (1995) Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 46(5):355–367
Mytilineos J, Lempert M, Scherer S, Schwarz V, Opelz G (1998) Comparison of serological and DNA PCR-SSP typing results for HLA-A and HLA-B in 421 black individuals: a collaborative transplant study report. Hum Immunol 59(8):512–517
Arya M, Shergill IS, Williamson M, Gommersall L, Arya N, Patel HR (2005) Basic principles of real-time quantitative PCR. Expert Rev Mol Diagn 5(2):209–219 Review
Li XY, Liu JZ, Gao JZ (2001) Determination of a real-time fluorotyping strategy for the HLA-DR locus. Transplant Proc 33(1–2):498–499
Dunn PP (2015) Novel approaches and Technologies in Molecular HLA typing. Methods Mol Biol 1310:213–230
Kuzio S, Hanguehard A, Morelle M, Ronsin C (2004) Rapid screening for HLA-B27 by a TaqMan-PCR assay using sequence specific primers and a minor groove binder probe, a novel type of TaqMan probe. J Immunol Methods 287(1–2):179–186
Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 74(12):5463–5467
De Santis D, Dinauer D, Duke J et al (2013) 16th IHIW: review of HLA typing by NGS. Int J Immunogenet 40(1):72–76
Gandhi MJ, Ferriola D, Huang Y, Duke JL, Monos D (2017) Targeted next-generation sequencing for human leukocyte antigen typing in a clinical laboratory: metrics of relevance and considerations for its successful implementation. Arch Pathol Lab Med 141(6):806–812
Author information
Authors and Affiliations
Contributions
Both authors contributed significantly to the writing and preparation of this manuscript.
Corresponding author
Ethics declarations
The manuscript is an original work of all authors. All authors made a significant contribution to this study. All authors have read and approved the final version of the manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Madden, K., Chabot-Richards, D. HLA testing in the molecular diagnostic laboratory. Virchows Arch 474, 139–147 (2019). https://doi.org/10.1007/s00428-018-2501-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-018-2501-3